SOLARA · NSE
Solara Active Pharma Sciences Limited
₹742.05
+0.05% (+₹0.35)
Prev. close
₹741.7
Volume
2,60,108
Delivery %
44.6%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. It offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immuno-suppressant, loop diuretic, NSAIDs, anti-hyperkalaemia, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. The company also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical development, impurity synthesis, and regulatory support. In addition, it exports its products. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sandeep Shashikantha Rao M.Sc., PGDM
Headquarters
Chennai
Employees
1,669
Website
solara.co.inExchange
View on NSE ↗Key stats
Market cap
₹3,543.52 Cr
EPS (TTM)
₹-0.64
Beta (1Y · daily vs NIFTY 50)
0.82
Beta (5Y · monthly vs NIFTY 50)
1.79
Shares float
3.19 Cr
EPS · quarter ended Jun 2026
₹3.52
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,616.88 Cr | ₹1,268.34 Cr | ₹1,443.81 Cr | ₹1,288.92 Cr | ₹1,283.76 Cr | ₹1,368.98 Cr | |
| EBITDA | ₹414.64 Cr | ₹96.50 Cr | ₹149.75 Cr | ₹-279.98 Cr | ₹202.95 Cr | ₹169.13 Cr |
| ₹221.40 Cr | ₹-58.15 Cr | ₹-22.17 Cr | ₹-567.39 Cr | ₹54.00 L | ₹-7.41 Cr | |
| Diluted EPS | ₹64.52 | ₹-16.18 | ₹-5.68 | ₹-148.51 | ₹0.14 | ₹-1.68 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,613.58 Cr | ₹2,944.96 Cr | ₹2,899.06 Cr | ₹2,350.96 Cr | ₹2,231.84 Cr | ₹2,332.59 Cr | |
| — | ₹1,037.37 Cr | ₹1,012.85 Cr | ₹1,011.50 Cr | ₹796.08 Cr | ₹686.56 Cr | |
| Stockholders' equity | ₹1,588.53 Cr | ₹1,524.87 Cr | ₹1,500.22 Cr | ₹933.72 Cr | ₹1,094.24 Cr | ₹1,252.88 Cr |
Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹155.46 Cr | ₹-242.09 Cr | ₹156.25 Cr | ₹108.87 Cr | ₹212.82 Cr | ₹152.91 Cr | |
| Investing cash flow | ₹-106.30 Cr | ₹-242.82 Cr | ₹-81.14 Cr | ₹-3.51 Cr | ₹-36.83 Cr | ₹-98.83 Cr |
| ₹92.49 Cr | ₹333.60 Cr | ₹-112.76 Cr | ₹-105.65 Cr | ₹-180.48 Cr | ₹-53.55 Cr | |
| Capital expenditure | ₹-174.48 Cr | ₹-208.59 Cr | ₹-111.31 Cr | ₹-41.06 Cr | ₹-39.94 Cr | ₹-52.82 Cr |
| End cash position | ₹197.69 Cr | ₹46.38 Cr | ₹8.73 Cr | ₹8.44 Cr | ₹3.95 Cr | ₹4.48 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Jun 21–Sep 21(2Q) | Dec 21 | Mar 22 | Jun 22–Dec 22(3Q) | Mar 23 | Jun 23 | Sep 23 | Dec 23–Mar 24(2Q) | Jun 24–Sep 24(3Q) | Dec 24 | Mar 25 | Jun 25–Sep 25(2Q) | Dec 25–May 26(3Q) | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 41.07% | 39.51% | 39.71% | 40.40% | 40.97% | 39.31% | 37.19% | 30.49% | 37.27% | 37.23% | 37.94% | 42.01% | 42.00% | 41.93% |
| Public | 58.93% | 60.49% | 60.29% | 59.60% | 59.03% | 60.69% | 62.81% | 69.51% | 62.73% | 62.77% | 62.06% | 57.99% | 58.00% | 58.07% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Solara Active Pharma Sciences Limited | ₹3,543.52 Cr | ₹742.05 | — | 2.83 | -0.6% | 0.55 | +7.1% | +8.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
4 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
SOLARA ACTIVE PHARMA SCIENCES Share Price Today Up 5%
Solara Active Pharma Sciences shares rose 5% to Rs 744.0. This increase occurred as the BSE HEALTHCARE index also gained 0.7%. The company reported a 55% year-over-year net profit growth for the quarter ended June 2026.